Core Insights - Oryzon Genomics has received a non-refundable grant of approximately €13.26 million (around $15 million) for its VANDAM project, which is part of the Med4Cure initiative aimed at supporting pharmaceutical research and innovation in Europe [1][3][4] - The grant covers 64% of the total budget for the VANDAM project, which is €20.68 million [1][4] - The VANDAM project focuses on developing therapies for rare neurodevelopmental disorders and neuroendocrine tumors, with a personalized medicine approach [2][3] Company Overview - Oryzon Genomics is a clinical-stage biopharmaceutical company based in Barcelona, Spain, specializing in epigenetics and personalized medicine for CNS disorders and oncology [5] - The company has two main drug candidates: vafidemstat, which is in Phase III readiness for CNS disorders, and iadademstat, currently in Phase II for oncology [5][6] - Oryzon's team consists of experienced professionals from the pharmaceutical industry, with operations in Barcelona, Boston, and San Diego [5] Project Details - The VANDAM project, which stands for "Validation of epigenetic Agents for Neuro-related rare Diseases Applying a personalized Medicine approach," is a 44-month initiative that began in January 2023 and will conclude in August 2026 [2][3] - The project aims to improve the quality of life for patients with rare diseases by developing targeted therapies based on a deeper understanding of the molecular causes of these conditions [2][3] Strategic Importance - The grant is considered a key component of Oryzon's clinical strategy, enabling the acceleration of clinical development for vafidemstat and further exploration of its therapeutic potential in managing aggression in rare diseases, including specific subtypes of Autism Spectrum Disorder (ASD) [2][4] - The funding will also support the investigation of iadademstat in rare tumors and genetically driven hematological diseases, areas with significant unmet medical needs [2][4] Collaborative Framework - Med4Cure is a pan-European project involving 14 scientific initiatives developed by 13 companies across six EU Member States, coordinated in Spain by the Centro para el Desarrollo Tecnológico y la Innovación (CDTI) [3] - Oryzon participates as an Associated Partner within this consortium, which is integrated into Spain's national Recovery and Resilience Plan [3]

Core Insights - VolitionRx Limited is focusing on commercializing its Nu.Q® platform in the human diagnostics market, with ongoing discussions with over ten companies, whose combined market value exceeds $600 billion [2][25]. - The Total Addressable Market (TAM) for cancer and sepsis diagnostics is approximately $25 billion annually, presenting substantial revenue opportunities for the company and its partners [3][25]. - The company has successfully raised $4.2 million through direct registered offerings, primarily from existing shareholders, demonstrating strong insider support [4]. Cancer Diagnostics - Significant progress has been made in the commercialization of cancer diagnostics, with two major companies in active negotiations regarding Nu.Q® and Capture-Seq™ technologies [5]. - A pivotal lung cancer screening study in Taiwan is advancing, with the potential market for the Nu.Q® test exceeding $1 billion across Taiwan, the U.S., U.K., and France [6][25]. - The Nu.Q® NETs program has shown strong clinical promise, with two large-scale studies completed, indicating a strong mortality signal and a link to organ failure [7]. Commercialization Efforts - Licensing discussions for Nu.Q® NETs are progressing well, with several companies completing technology transfers [8]. - The company recorded its first revenue for the CE-Marked Nu.Q® NETs automated product in Europe, with nine hospitals placing orders [9]. - The expansion of the Nu.Q® Vet Cancer Test is a priority, with supply agreements in place with leading industry players [10]. Revenue Growth Strategies - Central lab automation is being implemented to enhance revenue growth and meet increasing demand for the Nu.Q® Vet Cancer Test [11][12]. - The Nu.Q® Discover platform has achieved commercial milestones, including the first sale of a High Throughput Synthetic Sepsis Model, with discussions ongoing for additional projects [13][14]. - A collaboration with a leading pharmaceutical company for a human clinical study utilizing Volition's biomarkers has been established, highlighting the value of biomarkers in drug development [15]. Future Outlook - The company aims to double revenue in the Nu.Q® Discover pillar in 2025, supported by a growing customer base [16]. - The focus for the remainder of 2025 is to secure multiple licensing agreements in the human diagnostics space, mirroring the successful strategy in the veterinary market [19]. - The company is committed to achieving commercial partnerships for human applications, which is a long-term mission [20].

MADRID and CAMBRIDGE, Mass., April 24, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today the successful completion of a €30 million capital increase through the issuance of 12,765,958 new shares, priced at €2.35 per share. This pricing reflects a 15.44% discount to the 5-day volume-weighted average price (VWAP) of €2.779 per share prior to April 22, 2025, and a 19.38% discount to the ...

New "Decision to grant" communications in Europe and Japan MADRID and CAMBRIDGE, Mass., April 21, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that the European Patent Office has issued a "Decision to grant" communication for its European patent application EP20712563.4 relating to vafidemstat. The patent, titled "Methods of treating Attention Deficit Hyperactivity Disorder usin ...

Core Insights - The company aims to generate sufficient clinical data in 2024 to convince major players in the diagnostic and liquid biopsy markets of the significance of its Nu.Q® platform in oncology and sepsis [1] - In 2025, the focus will shift to signing multiple licensing deals for human indications, with strong interest from large companies for potential out-licensing and supply agreements [2] Financial Highlights - The company reported revenue of $1.2 million for 2024, representing a 59% increase compared to the previous year [7] - Nu.Q® Vet revenue increased by 75%, while Nu.Q® Discover revenue rose by 40% compared to 2023 [7] - Operating expenses decreased by 23% year-over-year, with a 31% reduction in the second half of 2024 [7] - Cash and cash equivalents as of December 31, 2024, totaled approximately $3.3 million, with additional funding of $1.8 million received post-year-end [7] Product Development and Market Expansion - Approximately 120,000 Nu.Q® Vet Cancer Tests were sold in 2024, with the test now available in over 20 countries [6] - A range of independent studies demonstrating the value of the Nu.Q® platform in sepsis and oncology has been completed [6] - The company is advancing several commercial discussions with significant players in the human diagnostic and liquid biopsy markets, which are valued in the multibillion-dollar range [6] Leadership and Governance - The Board of Directors was strengthened with the appointment of Timothy Still as Chair and Dr. Ethel Rubin as Independent Director, both bringing significant experience in the diagnostic sector [6]